$ANNX

Annexon, Inc. (ANNX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 d113783dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “ Agreement ”) dated as of July 30, 2026 (the “ Effective Date ”) among OX

Investing.com reports Wells Fargo named Annexon (ANNX) its top biotech pick, citing a favorable risk-reward and about 7-8x upside in its bull case. Wells Fargo said confidence rose after meetings with management. Annexon’s vonaprument is on track for Phase 3 data in Q4 2026, and tanruprubart’s BLA for Guillain-Barre could be a near-term catalyst. Needham raised its PT to $25; Citizens started at Underperform.

Biotech stocks rose Wednesday. Apollomics (APLM) jumped 22% after Nasdaq closed its MVLS compliance issue. Iovance (IOVA) gained 21% ahead of Q2 results; AVITA Medical (RCEL) rose 18% before Aug. 6 earnings; Annexon (ANNX) climbed 17% ahead of ARCHER II updates. Veradermics (MANE) gained 12% on Phase 2 hair-loss topline results.

Annexon (Nasdaq: ANNX) said it will present Phase 2 ARCHER analyses at ASRS 2026 on vonaprument in geographic atrophy (dry AMD). The talk will cover baseline factors linked to confirmed BCVA 15-letter loss, to guide patient selection for Phase 3 ARCHER II (659 patients). Topline data are expected in Q4 2026.

Annexon, Inc. (ANNX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001528115 0001528115 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11,

Satter Muneer A purchased 613,497 indirectly-held shares of Annexon, Inc. (ANNX) at $5.41 ($3.32M total) on 2026-05-28.

Annexon (NASDAQ:ANNX) announced earnings per share of ($0.32), meeting analyst expectations. The stock saw a slight dip to $4.96. Insider transactions were mixed with a director purchasing shares and an EVP selling, while hedge funds increased their holdings.

Annexon, Inc. (ANNX) has fully enrolled its Phase III ARCHER II trial for C1q inhibition in Geographic Atrophy (GA), with results anticipated in Q4. This novel approach aims to preserve vision by protecting photoreceptors, supported by strong functional and structural benefits observed in Phase II data. The trial is highly powered and aligned with regulators.

Annexon has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tanruprubart to treat Guillain-Barré syndrome (GBS), marking a significant milestone for the company and patients. Tanruprubart is an investigational, first-in-class antibody designed to rapidly block classical complement-driven inflammation, with Phase 3 study results demonstrating faster and more complete recovery for GBS patients. The company also plans a Biologics License Application (BLA) submission with the FDA in 2026, building on data from the ongoing FORWARD study.

Annexon (NASDAQ:ANNX) shares surged 9.6% following a significant price target increase from Wells Fargo & Company, which raised its target from $14.00 to $27.00 and reiterated an "overweight" rating. Insider buying also contributed to investor confidence, with Director Muneer A. Satter purchasing 500,000 shares and other insiders acquiring a total of 1.87 million shares recently. Despite a consensus "Hold" rating, the company's valuation metrics and recent institutional investment indicate continued interest.